Claims for Patent: 8,524,979

Summary for Patent: 8,524,979

Title:	Termination of transgene expression via transposon-mediated break
Abstract:	This invention provides a genetic construct comprising: (a) a DNA cut-and-paste transposon genetic unit which comprises a transposase gene flanked on either side by inverted repeat sequences and operably under the control of a first promoter; and (b) a transgene unit which comprises an expressable transgene, placed operably under the control of a second promoter; wherein the transposon genetic unit and the transgene unit are linked with one of the inverted repeat sequence located in an intron of the transgene. This invention also provides methods of transiently expressing a transgene in a stably transformed eukaryote. This invention further provides methods for obtaining marker-free transgenic plants.
Inventor(s):	Charng; Yuh-Chyang (Taipei, TW)
Assignee:	National Taiwan University (Taipei, TW)
Application Number:	12/102,266
Patent Claims:	1. A genetic construct comprising: a DNA cut-and-paste transposon genetic unit which comprises a first promoter which is inducible in plants, a transposase gene, a 5' inverted repeat sequence, which is located in an intron of the transposase gene, a poly(A) fragment, a transgene unit, and a 3' inverted repeat sequence which are operably linked in the 5' to 3' direction, wherein the transposase gene is operably under the control of the first promoter; and wherein the transgene unit comprises a second promoter and an expressable transgene which are operably linked in the 5' to 3' direction, wherein the transgene is operably under the control of the second promoter. 2. The genetic construct of claim 1, wherein the transposon is a maize Ac transposon, En/Spm transposon, Mutator (Mu) transposon, Drosophila P element, piggyBac transposon, or mice Sleeping Beauty (SB) transposon. 3. The genetic construct of claim 2, wherein the transposon is the maize Ac transposon. 4. The genetic construct of claim 3, wherein the transposase gene is an Ac transposase gene. 5. The genetic construct of claim 4, wherein the 5' and 3' inverted repeat sequences are Ac left and right terminal-inverted repeats. 6. The genetic construct of claim 1, wherein the first promoter is a PR-1a inducible promoter. 7. The genetic construct of claim 1, wherein the second promoter is a nopaline synthase promoter. 8. The genetic construct of claim 1, wherein the transgene is a selectable marker. 9. A method of transiently expressing a transgene in a stably transformed plant, comprising the following steps: (a) stably transforming the plant with a genetic construct, comprising a DNA cut-and-paste transposon genetic unit which comprises a first inducible promoter, a transposase gene, an 5' inverted repeat sequence, which is located in an intron of the transposase gene, a poly(A) fragement, a transgene unit, and a 3' inverted repeat sequence which are operably linked in the 5' to 3' direction, wherein the transposase gene is operably under the control of the first promoter; and wherein the transgene unit comprises a second promoter and an expressable transgene which are operably linked in the 5' to 3' direction, wherein the transgene is operably under the control of the second promoter; (b) expressing the transgene of the genetic construct in the plant; and (c) expressing the transposase gene of the genetic construct in the plant. 10. The method of claim 9, wherein the step (c) is inducible when the first promoter of the genetic construct is an inducible promoter, and a corresponding inducing agent of the inducible promoter is applied to the plant at the step (c). 11. The method of claim 9, wherein the plant is maize, rice, a fruit-bearing plant or a flowering plant. 12. The method of claim 9, wherein the transposase gene is able to be inducibly expressed only one-time. 13. The method of claim 9, wherein the first promoter is a PR-1a inducible promoter. 14. The method of claim 9, wherein the second promoter is a nopaline synthase promoter.

Details for Patent 8,524,979

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26